FDA approves Myxredlin, first ready-to-use insulin for intravenous infusion

"Insulin is in the top five drug classes involved with medication errors, and more than 30 percent of those errors result in patient harm,"¹ said Robert Felicelli, president, Pharmaceuticals, Baxter. "When a patient requires intravenous insulin in the hospital, pharmacists have to manually admix insulin for treatment. With the launch of Myxredlin, clinicians will have access to a convenient, reliable presentation of ready-to-use insulin that can help ensure faster delivery to patients, streamlined workflow for pharmacists and nurses, and less waste for hospitals."

Myxredlin is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus. Myxredlin is intended for use only in acute care settings under medical supervision.

Indication

Myxredlin is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Contraindications

• During episodes of hypoglycemia


• Hypersensitivity to insulin human or any of the excipients in Myxredlin

Warnings and Precautions

• Administer Myxredlinintravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels. Hypokalemia may be life-threatening.